Benzinga | Feb 16, 2021 04:53AM EST

SVB Leerink Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to $178

SVB Leerink analyst Joseph Schwartz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Outperform and raises the price target from $115 to $178.